Huntington Ingalls Industries Inc vs Tilray Brands Inc — how do they compare? Huntington Ingalls Industries Inc trades at $264.8 (market cap $10.44B), while Tilray Brands Inc trades at $3.54 (market cap $530.54M). The key difference: Huntington Ingalls Industries Inc is far larger — about 19.7× Tilray Brands Inc's market cap, and Huntington Ingalls Industries Inc pays a 2.08% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Huntington Ingalls Industries Inc for 28 Days and Tilray Brands Inc for 31 Days on average.
| HII | TLRY | |
|---|---|---|
Market Cap | $10.44B | $530.54M |
Volume | 440,462 | 9,099,075 |
Sector | Industrials | Health |
52-Week High | $453.73 | $17.20 |
52-Week Low | $257.05 | $3.54 |
Typical Hold Time | 28 Days | 31 Days |
Enterprise Value | $13.37B | $684.46M |
Dividend Yield | 2.08% | — |
Signals from Pluang's Aura AI — not financial advice
HII trades at $265.02, up 1.67% today, with a bearish technical signal but strong fundamentals. The company reported consistent earnings beats, with Q2 2026 EPS of $5.27 surpassing expectations. Recent contract wins, including a $5.1 billion aircraft carrier overhaul, bolster revenue visibility from a $57.3 billion backlog. Valuation ratios appear reasonable with a P/E of 15.78 and P/S of 0.79.
The outlook is supported by robust defense budgets and contract momentum, but technical weakness and mixed analyst sentiment (40.7% buy, 55.6% hold) suggest near-term caution. Key risks include execution on large projects and defense spending cycles. The consensus price target of $363.67 implies significant upside if operational targets are met.
TLRY trades at $3.59, down 3.36% on the day and near 52-week lows, with a bearish technical signal. The company reported revenue of $821.31M for 2025 but posted a net loss of -$2.19B, missing earnings expectations for four consecutive quarters. While analyst consensus shows 70% hold ratings, the stock faces significant profitability challenges with negative margins and cash flow concerns despite some revenue growth projections.
The outlook remains challenging with persistent losses and negative cash flow, though the stock trades at discounted valuation multiples. Key risks include ongoing profitability struggles and cannabis regulatory uncertainty. Potential catalysts include upcoming Q1 2027 earnings on October 8, 2026, and potential marijuana reform developments that could benefit the company's positioning.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Huntington Ingalls is the largest military shipbuilder in the U.S. and a provider of professional services to government and industry partners, specializing in nuclear-powered submarines and aircraft carriers.
Read more on HII →Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →